(Total Views: 536)
Posted On: 07/07/2025 8:37:28 PM
Post# of 155076
The FDA ..HAS approved LL @ 700mg CRC before
Trial didn't enroll in 2023 --- fkn Amarex...
But ,,,,this should make anyone VERRRY confident on our now CRC
Leronlimab will be administered subcutaneously at a weekly dose of 700 mg in combination with staring dose of 80 mg Regorafenib at first week of the Cycle 1, followed by escalation of Regorafenib dose to 120 mg and 160 mg in second and third weeks of Cycle 1, respectively. No Regorafenib will be administered during the fourth week.
NCT05730673
https://clinicaltrials.gov/study/NCT05730673?...;tab=table
Trial didn't enroll in 2023 --- fkn Amarex...
But ,,,,this should make anyone VERRRY confident on our now CRC
Leronlimab will be administered subcutaneously at a weekly dose of 700 mg in combination with staring dose of 80 mg Regorafenib at first week of the Cycle 1, followed by escalation of Regorafenib dose to 120 mg and 160 mg in second and third weeks of Cycle 1, respectively. No Regorafenib will be administered during the fourth week.
NCT05730673
https://clinicaltrials.gov/study/NCT05730673?...;tab=table
(7)
(0)
